Coagulation parameters in gastrointestinal cancer patients with venous thromboembolism.
[BACKGROUND] Patients with gastrointestinal (GI) cancer are at increased risk of venous thromboembolism (VTE), which is an important cause of mortality.
- 표본수 (n) 81
- 95% CI 1.21-81.54
- OR 9.95
- 연구 설계 case-control
APA
Fan D, Lanting V, et al. (2026). Coagulation parameters in gastrointestinal cancer patients with venous thromboembolism.. Thrombosis research, 258, 109587. https://doi.org/10.1016/j.thromres.2026.109587
MLA
Fan D, et al.. "Coagulation parameters in gastrointestinal cancer patients with venous thromboembolism.." Thrombosis research, vol. 258, 2026, pp. 109587.
PMID
41534386
Abstract
[BACKGROUND] Patients with gastrointestinal (GI) cancer are at increased risk of venous thromboembolism (VTE), which is an important cause of mortality. Risk stratification of VTE in GI cancer remains challenging.
[OBJECTIVES] To investigate whether assessment of the coagulation system can predict VTE risk in three GI tumor types.
[METHODS] We used a nested case-control design within the MICA cohort (total N = 81), including 27 patients who developed VTE during follow-up and 54 matched non-VTE controls. The subgroup distribution was esophageal cancer (n = 42), pancreatic cancer (n = 18), and colorectal cancer (n = 21). Plasma samples were analyzed using a multifaceted approach incorporating tissue factor (TF) measurement, thrombin generation, and endothelial function testing within an artificial vessel model. Conditional logistic regression was used to evaluate associations between coagulation parameters and VTE risk.
[RESULTS] TF concentrations did not differ between patients with and without VTE across esophageal, colorectal, and pancreatic cancers. In esophageal cancer, prolonged lag time, as well as higher endogenous thrombin potential and peak values in the artificial vessel model, were significantly associated with an increased risk of VTE (OR = 9.95, 95% CI 1.21-81.54; OR = 5.15, 95% CI 1.07-25.00; OR = 10.75, 95% CI 1.31-90.91). No significant differences in coagulation-related parameters were observed in pancreatic or colorectal cancer patients.
[CONCLUSION] Abnormal coagulation may be associated with VTE risk mainly in esophageal cancer, suggesting that VTE biomarkers may differ by cancer type and require further investigation in larger cohorts.
[OBJECTIVES] To investigate whether assessment of the coagulation system can predict VTE risk in three GI tumor types.
[METHODS] We used a nested case-control design within the MICA cohort (total N = 81), including 27 patients who developed VTE during follow-up and 54 matched non-VTE controls. The subgroup distribution was esophageal cancer (n = 42), pancreatic cancer (n = 18), and colorectal cancer (n = 21). Plasma samples were analyzed using a multifaceted approach incorporating tissue factor (TF) measurement, thrombin generation, and endothelial function testing within an artificial vessel model. Conditional logistic regression was used to evaluate associations between coagulation parameters and VTE risk.
[RESULTS] TF concentrations did not differ between patients with and without VTE across esophageal, colorectal, and pancreatic cancers. In esophageal cancer, prolonged lag time, as well as higher endogenous thrombin potential and peak values in the artificial vessel model, were significantly associated with an increased risk of VTE (OR = 9.95, 95% CI 1.21-81.54; OR = 5.15, 95% CI 1.07-25.00; OR = 10.75, 95% CI 1.31-90.91). No significant differences in coagulation-related parameters were observed in pancreatic or colorectal cancer patients.
[CONCLUSION] Abnormal coagulation may be associated with VTE risk mainly in esophageal cancer, suggesting that VTE biomarkers may differ by cancer type and require further investigation in larger cohorts.
MeSH Terms
Humans; Venous Thromboembolism; Male; Female; Middle Aged; Gastrointestinal Neoplasms; Aged; Case-Control Studies; Blood Coagulation; Risk Factors
같은 제1저자의 인용 많은 논문 (4)
- [Erianin inhibits proliferation and migration of breast cancer cells by inhibiting Wnt/β-catenin signaling].
- Boosting Hydroxyl Migration over Palladium-Based Catalysts to Enhance the Alkaline Hydrogen Oxidation.
- Downregulation of MUC1 Enhances Antitumor Response in Colon Cancer Model by Decreasing PD-L1 Expression In Vivo and In Vitro.
- A Dual-Ion Synergistic Catalysis Utilizing Zn-Regulated CdSSe ECL Immunosensor Employed for the Ultrasensitive CA19-9 Detection.